Cartesian Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cartesian Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2017 to Q3 2024.
  • Cartesian Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -272 %, a 393% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -272 -365 -393% Sep 30, 2024
Q2 2024 -231 -332 -330% Jun 30, 2024
Q1 2024 -233 -334 -332% Mar 31, 2024
Q4 2023 -269 -378 -347% Dec 31, 2023
Q3 2023 92.8 -73 -44% Sep 30, 2023
Q2 2023 101 -242 -70.7% Jun 30, 2023
Q1 2023 101 -980 -90.7% Mar 31, 2023
Q4 2022 109 +3.63K Dec 31, 2022
Q3 2022 166 +1.41K Sep 30, 2022
Q2 2022 343 +1.87K Jun 30, 2022
Q1 2022 1.08K +2.21K Mar 31, 2022
Q4 2021 -3.52K -2.34K -198% Dec 31, 2021
Q3 2021 -1.24K +998 +44.6% Sep 30, 2021
Q2 2021 -1.53K +223 +12.7% Jun 30, 2021
Q1 2021 -1.13K -1.68K -305% Mar 31, 2021
Q4 2020 -1.18K -1.49K -481% Dec 31, 2020
Q3 2020 -2.24K -2.55K -816% Sep 30, 2020
Q2 2020 -1.75K -2.02K -755% Jun 30, 2020
Q1 2020 552 +39.9 +7.8% Mar 31, 2020
Q4 2019 310 -5.95 -1.88% Dec 31, 2019
Q3 2019 312 +148 +89.9% Sep 30, 2019
Q2 2019 268 +160 +148% Jun 30, 2019
Q1 2019 512 +435 +562% Mar 31, 2019
Q4 2018 316 +246 +350% Dec 31, 2018
Q3 2018 164 +102 +161% Sep 30, 2018
Q2 2018 108 +55.2 +105% Jun 30, 2018
Q1 2018 77.4 +29.6 +62% Mar 31, 2018
Q4 2017 70.1 Dec 31, 2017
Q3 2017 62.9 Sep 30, 2017
Q2 2017 52.7 Jun 30, 2017
Q1 2017 47.8 Mar 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.